Epigenetic histone modulations of PPARγ and related pathways contribute to olanzapine-induced metabolic disorders

Buhagiar, 2019, Association of first- vs. Second-generation antipsychotics with lipid abnormalities in individuals with severe mental illness: a systematic review and meta-analysis, Clin. Drug Investig., 39, 253, 10.1007/s40261-019-00751-2 Deng, 2013, Effects of antipsychotic medications on appetite, weight, and insulin resistance, Endocrinol. Metab. Clin. North Am., 42, 545, 10.1016/j.ecl.2013.05.006 Vantaggiato, 2019, Pozzi M. Antipsychotics promote metabolic disorders disrupting cellular lipid metabolism and trafficking, Trends Endocrinol. Metab., 30, 189, 10.1016/j.tem.2019.01.003 Chen, 2017, Molecular mechanisms of antipsychotic drug-induced diabetes, Front. Neurosci., 11 Rojo, 2015, Metabolic syndrome and obesity among users of second generation antipsychotics: a global challenge for modern psychopharmacology, Pharmacol. Res., 101, 74, 10.1016/j.phrs.2015.07.022 Lian, 2014, Preventing olanzapine-induced weight gain using betahistine: a study in a rat model with chronic olanzapine treatment, PLoS One, 9, 10.1371/journal.pone.0104160 Liu, 2017, Time-dependent changes and potential mechanisms of glucose-lipid metabolic disorders associated with chronic clozapine or olanzapine treatment in rats, Sci. Rep., 7, 2762, 10.1038/s41598-017-02884-w Xu, 2019, Atypical antipsychotics-induced metabolic syndrome and nonalcoholic fatty liver disease: a critical review, Neuropsychiatr. Dis. Treat., 15, 2087, 10.2147/NDT.S208061 Mota de Sa, 2017, Transcriptional regulation of adipogenesis, Compr. Physiol., 7, 635, 10.1002/cphy.c160022 Sanders, 2016, De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose, Biol. Rev. Camb. Philos. Soc., 91, 452, 10.1111/brv.12178 Fajas, 1999, Regulation of peroxisome proliferator-activated receptor gamma expression by adipocyte differentiation and determination factor 1/sterol regulatory element binding protein 1: implications for adipocyte differentiation and metabolism, Mol. Cell. Biol., 19, 5495, 10.1128/MCB.19.8.5495 Kim, 1998, ADD1/SREBP1 activates PPARgamma through the production of endogenous ligand, Proc Natl Acad Sci U S A., 95, 4333, 10.1073/pnas.95.8.4333 Lefterova, 2014, PPARgamma and the global map of adipogenesis and beyond, Trends Endocrinol. Metab., 25, 293, 10.1016/j.tem.2014.04.001 Wu, 2013, Role of kruppel-like transcription factors in adipogenesis, Dev. Biol., 373, 235, 10.1016/j.ydbio.2012.10.031 Wakao, 2011, Constitutively active Stat5A and Stat5B promote adipogenesis, Environ. Health Prev. Med., 16, 247, 10.1007/s12199-010-0193-7 Kaltenecker, 2017, Adipocyte STAT5 deficiency promotes adiposity and impairs lipid mobilisation in mice, Diabetologia., 60, 296, 10.1007/s00125-016-4152-8 Liu, 2019, Simvastatin improves olanzapine-induced dyslipidemia in rats through inhibiting hepatic mTOR signaling pathway, Acta Pharmacol. Sin., 1049, 10.1038/s41401-019-0212-1 Ferno, 2009, Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver, Psychopharmacology (Berl.), 203, 73, 10.1007/s00213-008-1370-x Ferno, 2015, Olanzapine depot exposure in male rats: dose-dependent lipogenic effects without concomitant weight gain, Eur. Neuropsychopharmacol., 25, 923, 10.1016/j.euroneuro.2015.03.002 Ho, 2017, Signaling, epigenetic and TranscriptionalRegulation of hepatic lipogenesis, J Metab., 1, 3 Wang, 2017, From histones to RNA: role of methylation in signal proteins involved in adipogenesis, Curr. Protein Pept. Sci., 18, 589, 10.2174/1389203717666160627082444 Chase, 2013, Epigenetic developmental programs and adipogenesis: implications for psychotropic induced obesity, Epigenetics., 8, 1133, 10.4161/epi.26027 Deng, 2015, Histone methyltransferases and demethylases: regulators in balancing osteogenic and adipogenic differentiation of mesenchymal stem cells, Int. J. Oral Sci., 7, 197, 10.1038/ijos.2015.41 Weston-Green, 2013, Second generation antipsychotic-induced type 2 diabetes: a role for the muscarinic M3 receptor, CNS Drugs, 27, 1069, 10.1007/s40263-013-0115-5 Correll, 2010, From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics, Eur. Psychiatry, 25, S12, 10.1016/S0924-9338(10)71701-6 Yu, 2014, A rat RNA-Seq transcriptomic BodyMap across 11 organs and 4 developmental stages, Nat. Commun., 5, 3230, 10.1038/ncomms4230 Vatamaniuk, 2003, Acetylcholine affects rat liver metabolism via type 3 muscarinic receptors in hepatocytes, Life Sci., 72, 1871, 10.1016/S0024-3205(02)02506-7 Deng, 2012, Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model, J Psychopharmacol., 26, 1271, 10.1177/0269881112449396 Lian, 2013, Effects of olanzapine and betahistine co-treatment on serotonin transporter, 5-HT2A and dopamine D2 receptor binding density, Prog. Neuropsychopharmacol. Biol. Psychiatry, 47, 62, 10.1016/j.pnpbp.2013.08.005 Kapur, 2003, Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy, J. Pharmacol. Exp. Ther., 305, 625, 10.1124/jpet.102.046987 Johnson, 2011, Mechanism-based pharmacokinetic–Pharmacodynamic modeling of the dopamine D2 receptor occupancy of olanzapine in rats, Pharm. Res., 28, 2490, 10.1007/s11095-011-0477-7 Aravagiri, 1999, Pharmacokinetics and tissue distribution of olanzapine in rats, Biopharm. Drug Dispos., 20, 369, 10.1002/1099-081X(199911)20:8<369::AID-BDD200>3.0.CO;2-6 Liu, 2015, QoL evaluation of olanzapine for chemotherapy-induced nausea and vomiting comparing with 5-HT3 receptor antagonist, Eur. J. Cancer Care, 24, 436, 10.1111/ecc.12260 Lecoutre, 2018, Reduced PPARgamma2 expression in adipose tissue of male rat offspring from obese dams is associated with epigenetic modifications, FASEB J., 32, 2768, 10.1096/fj.201700997R Tsai, 2004, Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARgamma, J. Clin. Invest., 114, 240, 10.1172/JCI200420964 Barroso, 1999, Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension, Nature., 402, 880, 10.1038/47254 Gumbilai, 2016, Fat mass reduction with adipocyte hypertrophy and insulin resistance in heterozygous PPARgamma mutant rats, Diabetes., 65, 2954, 10.2337/db15-1422 Okamura, 2010, Role of histone methylation and demethylation in adipogenesis and obesity, Organogenesis., 6, 24, 10.4161/org.6.1.11121 Matsumura, 2015, H3K4/H3K9me3 bivalent chromatin domains targeted by lineage-specific DNA methylation pauses adipocyte differentiation, Mol. Cell, 60, 584, 10.1016/j.molcel.2015.10.025 Lee, 2014, Transcriptional and epigenetic regulation of PPARgamma expression during adipogenesis, Cell Biosci., 4, 29, 10.1186/2045-3701-4-29 Wang, 2013, Histone H3K9 methyltransferase G9a represses PPARgamma expression and adipogenesis, EMBO J., 32, 45, 10.1038/emboj.2012.306 Lee, 2008, Targeted inactivation of MLL3 histone H3–Lys-4 methyltransferase activity in the mouse reveals vital roles for MLL3 in adipogenesis, Proc. Natl. Acad. Sci., 105, 19229, 10.1073/pnas.0810100105 Lee, 2013, H3K4 mono- and di-methyltransferase MLL4 is required for enhancer activation during cell differentiation, eLife., 2, 10.7554/eLife.01503 Cristancho, 2013, Double SET point: G9a makes its mark in adipogenesis, EMBO J., 32, 4, 10.1038/emboj.2012.320 Li, 2013, G9a is transactivated by C/EBPbeta to facilitate mitotic clonal expansion during 3T3-L1 preadipocyte differentiation, Am. J. Physiol. Endocrinol. Metab., 304, E990, 10.1152/ajpendo.00608.2012 Okuno, 2013, Epigenetic regulation of adipogenesis by PHF2 histone demethylase, Diabetes., 62, 1426, 10.2337/db12-0628 Cheng, 2018, KDM4B protects against obesity and metabolic dysfunction, Proc. Natl. Acad. Sci., 115, E5566, 10.1073/pnas.1721814115 Barbaro, 2018, Commentary: the histone demethylase Phf2 acts as a molecular checkpoint to prevent NAFLD progression during obesity, Front. Genet., 9 Hino, 2012, FAD-dependent lysine-specific demethylase-1 regulates cellular energy expenditure, Nat. Commun., 3, 758, 10.1038/ncomms1755 Siersbaek, 2011, Extensive chromatin remodelling and establishment of transcription factor’ hotspots’ during early adipogenesis, EMBO J., 30, 1459, 10.1038/emboj.2011.65 Hughes, 2016, Probing the Complex Binding Modes of the PPARgamma Partial Agonist 2-Chloro-N-(3-chloro-4-((5-chlorobenzo[d]thiazol-2-yl)thio)phenyl)-4-(trifluorome thyl)benzenesulfonamide (T2384) to Orthosteric and Allosteric Sites with NMR Spectroscopy, J. Med. Chem., 59, 10335, 10.1021/acs.jmedchem.6b01340 Marciano, 2015, Identification of Bexarotene as a PPARgamma antagonist with HDX, PPAR Res., 2015, 10.1155/2015/254560 Oishi, 2005, Kruppel-like transcription factor KLF5 is a key regulator of adipocyte differentiation, Cell Metab., 1, 27, 10.1016/j.cmet.2004.11.005 Pei, 2011, Kruppel-like factor KLF9 regulates PPARgamma transactivation at the middle stage of adipogenesis, Cell Death Differ., 18, 315, 10.1038/cdd.2010.100 Mori, 2005, Role of Kruppel-like factor 15 (KLF15) in transcriptional regulation of adipogenesis, J. Biol. Chem., 280, 12867, 10.1074/jbc.M410515200 Drori, 2005, Hic-5 regulates an epithelial program mediated by PPARgamma, Genes Dev., 19, 362, 10.1101/gad.1240705 Liu, 2015, Acute effects of oral olanzapine treatment on the expression of fatty acid and cholesterol metabolism-related gene in rats, Life Sci., 128, 72, 10.1016/j.lfs.2015.01.033 Li, 2009, Hepatic muscarinic acetylcholine receptors are not critically involved in maintaining glucose homeostasis in mice, Diabetes., 58, 2776, 10.2337/db09-0522 Harkitis, 2015, Konstandi M. Dopamine D2-Receptor antagonists down-regulate CYP1A1/2 and CYP1B1 in the rat liver, PLoS One, 10, 10.1371/journal.pone.0128708 Jadeja, 2019, M3 Muscarinic receptor activation reduces hepatocyte lipid accumulation via CaMKKβ/AMPK pathway, Biochem. Pharmacol., 169, 113613, 10.1016/j.bcp.2019.08.015 Li, 2016, Berberine alleviates olanzapine-induced adipogenesis via the AMPKα–SREBP pathway in 3T3-L1 cells, Int. J. Mol. Sci., 17, 1865, 10.3390/ijms17111865 Oh, 2011, Atypical antipsychotic drugs perturb AMPK-dependent regulation of hepatic lipid metabolism, Am. J. Physiol. Endocrinol. Metab., 300, E624, 10.1152/ajpendo.00502.2010 Gongol, 2018, AMPK: An epigenetic landscape modulator, Int. J. Mol. Sci., 19, 3238, 10.3390/ijms19103238 Steinkopf, 2008, The psychotropic drug olanzapine (Zyprexa®) increases the area of acid glycerophospholipid monolayers, Biophys. Chem., 134, 39, 10.1016/j.bpc.2008.01.003 Kristiana, 2010, Antipsychotic drugs upregulate lipogenic gene expression by disrupting intracellular trafficking of lipoprotein-derived cholesterol, Pharmacogenomics J., 10, 396, 10.1038/tpj.2009.62 Kim, 2018, Histone H3K9 demethylase JMJD2B induces hepatic steatosis through upregulation of PPARγ2, Sci. Rep., 8, 13734, 10.1038/s41598-018-31953-x